Zentalis Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $241.4M
- Price
- $2.55
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.49%
- Volume
- 819.6K
About
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Quick stats
Shares outstanding94.7M
Computed float77.1M
Float / shares81.4%
Cash runway (months)8.5
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001725160
Websitehttps://www.zentalis.com
AI Summary
AI-generated1/26
minorneutralother
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zentalis Pharmaceuticals granted non-qualified stock options to purchase 62,000 shares to three newly hired employees under its 2022 Inducement Plan.
The grants were made under Nasdaq Listing Rule 5635(c)(4), carry an exercise price of $2.605 (the grant-date close), a 10-year term, and four-year vesting.
This is routine compensation-related boilerplate with no bearing on the company's clinical programs, including the WEE1 inhibitor azenosertib.